ロード中...
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia
The successful use of PARP1 inhibitors like olaparib (Loparza(®)) in the treatment of BRCA1/2- deficient breast cancer has provided clinical proof of concept for applying personalized medicine based on synthetic lethality to the treatment of cancer. Unfortunately, all marketed PARP1 inhibitors act b...
保存先:
| 出版年: | Med Chem Res |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7560981/ https://ncbi.nlm.nih.gov/pubmed/33071527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00044-020-02537-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|